Skip to main content

Hyponatremia News

FDA Medwatch Alert: Samsca (tolvaptan): Drug Warning - Potential Risk of Liver Injury

ISSUE: Otsuka and FDA notified healthcare professionals of significant liver injury associated with the use of Samsca. In a double-blind, 3-year, placebo-controlled trial in about 1400 patients with...

Ask a question

To post your own question to our community, sign in or create an account.